FOLFIRI.3

DRUG3 trials

Sponsors

Asan Medical Center, Federation Francophone de Cancerologie Digestive

Conditions

Metastatic Pancreatic Cancer

Phase 2

Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer

CompletedNCT00786006

Asan Medical CenterMetastatic Pancreatic Cancer

Start: 2007-03-31End: 2009-09-30Updated: 2011-12-06

First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem

CompletedNCT02352337

Federation Francophone de Cancerologie DigestiveMetastatic Pancreatic Cancer

Start: 2015-01-12End: 2021-08-31Updated: 2024-07-10

FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine

CompletedNCT02827201

Federation Francophone de Cancerologie DigestiveMetastatic Pancreatic Cancer

Start: 2015-11-30End: 2021-03-31Updated: 2024-07-09

Related Papers

Abstract 3654: Comparative efficacy of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: computing IPTW estimator while limiting patient data exposure with federated learning across 3 institutions

Cancer Research2025-04-21

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer

The Oncologist2024-05-04

Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.

Journal of Clinical Oncology2019-05-203 citations

Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer

Annals of Oncology2018-10-011 citations

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

Journal of Clinical Oncology2018-05-2053 citations

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

Journal of Clinical Oncology2018-05-2010 citations